Li-Feng Huang1, Yong-Ming Yao1, Zhi-Yong Sheng1. 1. Department of Microbiology and Immunology, Burns Institute, First Hospital Affiliated to the Chinese People's Liberation Army General Hospital, Beijing 100048, China.
Abstract
BACKGROUND: High mobility group box 1 protein (HMGB1) is a highly conserved, ubiquitous protein in the nuclei and cytoplasm of nearly all cell types. HMGB1 is secreted into the extracellular milieu and acts as a proinfl ammatory cytokine. In this article we reviewed briefl y the cellular immune response mediated by HMGB1 in infl ammation and sepsis. METHODS: This systemic review is mainly based on our own work and other related reports. RESULTS: HMGB1 can actively affect the immune functions of many types of cells including T lymphocytes, regulatory T cells (Tregs), dendritic cells (DCs), macrophages, and natural killer cells (NK cells). Various cellular responses can be mediated by HMGB1 which binds to cell-surface receptors [e.g., the receptor for advanced glycation end products (RAGE), Toll-like receptor (TLR)2, and TLR4]. Anti-HMGB1 treatment, such as anti-HMGB1 polyclonal or monoclonal antibodies, inhibitors (e.g., ethyl pyruvate) and antagonists (e.g., A box), can protect against sepsis lethality and give a wider window for the treatment opportunity. CONCLUSION: HMGB1 is an attractive target for the development of new therapeutic strategies in the treatment of patients with septic complications.
BACKGROUND:High mobility group box 1 protein (HMGB1) is a highly conserved, ubiquitous protein in the nuclei and cytoplasm of nearly all cell types. HMGB1 is secreted into the extracellular milieu and acts as a proinfl ammatory cytokine. In this article we reviewed briefl y the cellular immune response mediated by HMGB1 in infl ammation and sepsis. METHODS: This systemic review is mainly based on our own work and other related reports. RESULTS:HMGB1 can actively affect the immune functions of many types of cells including T lymphocytes, regulatory T cells (Tregs), dendritic cells (DCs), macrophages, and natural killer cells (NK cells). Various cellular responses can be mediated by HMGB1 which binds to cell-surface receptors [e.g., the receptor for advanced glycation end products (RAGE), Toll-like receptor (TLR)2, and TLR4]. Anti-HMGB1 treatment, such as anti-HMGB1 polyclonal or monoclonal antibodies, inhibitors (e.g., ethyl pyruvate) and antagonists (e.g., A box), can protect against sepsis lethality and give a wider window for the treatment opportunity. CONCLUSION:HMGB1 is an attractive target for the development of new therapeutic strategies in the treatment of patients with septic complications.
Entities:
Keywords:
Cytokine; High mobility group box 1 protein; Immunological effect; Sepsis; Signal transduction
Authors: Arno Mohr; Johannes Polz; Elisabeth M Martin; Sybille Griessl; Anja Kammler; Christian Pötschke; Anja Lechner; Barbara M Bröker; Sven Mostböck; Daniela N Männel Journal: Eur J Immunol Date: 2011-12-20 Impact factor: 5.532
Authors: Maria Letizia Giardino Torchia; Elena Ciaglia; Anna Maria Masci; Laura Vitiello; Manuela Fogli; Andrea la Sala; Domenico Mavilio; Luigi Racioppi Journal: PLoS One Date: 2010-06-10 Impact factor: 3.240
Authors: Huan Yang; Mahendar Ochani; Jianhua Li; Xiaoling Qiang; Mahira Tanovic; Helena E Harris; Srinivas M Susarla; Luis Ulloa; Hong Wang; Robert DiRaimo; Christopher J Czura; Haichao Wang; Jesse Roth; H Shaw Warren; Mitchell P Fink; Matthew J Fenton; Ulf Andersson; Kevin J Tracey Journal: Proc Natl Acad Sci U S A Date: 2003-12-26 Impact factor: 11.205
Authors: U Andersson; H Wang; K Palmblad; A C Aveberger; O Bloom; H Erlandsson-Harris; A Janson; R Kokkola; M Zhang; H Yang; K J Tracey Journal: J Exp Med Date: 2000-08-21 Impact factor: 14.307
Authors: Eliézer Silva; Rogério Da Hora Passos; Maurício Beller Ferri; Luiz Francisco Poli de Figueiredo Journal: Clinics (Sao Paulo) Date: 2008-02 Impact factor: 2.365
Authors: Robert Słotwiński; Agnieszka Sarnecka; Aleksandra Dąbrowska; Katarzyna Kosałka; Ewelina Wachowska; Barbara J Bałan; Marta Jankowska; Teresa Korta; Grzegorz Niewiński; Andrzej Kański; Małgorzata Mikaszewska-Sokolewicz; Mohammad Omidi; Krystyna Majewska; Sylwia M Słotwińska Journal: Cent Eur J Immunol Date: 2015-10-15 Impact factor: 2.085